34156-56-4
34156-56-4
Chemical Structure
Foscarnet trisodium hexahydrate
Synonym(s): Trisodium phosphonoformate hexahydrate; Phosphonoformic acid trisodium salt hexahydrate
- CAS No.: 34156-56-4
- Formula:CH12Na3O11P
- Molecular Weight:300.04
SMILES: O=C(P(O[Na])(O[Na])=O)O[Na].[6H2O]
Biological Activity: Foscarnet trisodium hexahydrate (Trisodium phosphonatoformate hexahydrate) is a viral DNA polymerase activity inhibitor, leading to reversible suppression of viral replication. Foscarnet trisodium hexahydrate is an antiherpesvirus agent used in cytomegalovirus retinitis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Foscarnet trisodium hexahydrate | 99.50% | Foscarnet trisodium hexahydrate (Trisodium phosphonatoformate hexahydrate) is a viral DNA polymerase activity inhibitor, leading to reversible suppression of viral replication. Foscarnet trisodium hexahydrate is an antiherpesvirus agent used in cytomegalovirus retinitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Foscarnet trisodium hexahydrate (Standard) | ≥98% | Foscarnet (trisodium hexahydrate) (Standard) is the analytical standard of Foscarnet (trisodium hexahydrate). This product is intended for research and analytical applications. Foscarnet trisodium hexahydrate (Trisodium phosphonatoformate hexahydrate) is a viral DNA polymerase activity inhibitor, leading to reversible suppression of viral replication. Foscarnet trisodium hexahydrate is an antiherpesvirus agent used in cytomegalovirus retinitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zahn KE, Doublié S, et al. Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase. J Biol Chem. 2011 Jul 15;286(28):25246-55. [Content Brief]
- [2]. Oberg B, et al. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).Pharmacol Ther. 1982;19(3):387-415. [Content Brief]
- [3]. Hakki M, et al. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.Curr Hematol Malig Rep. 2020 Jan 24. [Content Brief]
